董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dipti Amin | 女 | Director | 59 | 12.73万美元 | 未持股 | 2023-07-20 |
| Anula Jayasuriya | 女 | Director | 66 | 12.73万美元 | 未持股 | 2023-07-20 |
| Don M. Bailey | 男 | Director | 77 | 13.33万美元 | 未持股 | 2023-07-20 |
| Neal C. Bradsher | 男 | Director | 57 | 13.40万美元 | 未持股 | 2023-07-20 |
| Deborah Andrews | 女 | Director | 65 | 15.40万美元 | 未持股 | 2023-07-20 |
| Alfred D. Kingsley | 男 | Chairman of the Board | 80 | 30.48万美元 | 未持股 | 2023-07-20 |
| Brian M. Culley | 男 | Chief Executive Officer and Director | 52 | 237.25万美元 | 未持股 | 2023-07-20 |
| Michael H. Mulroy | 男 | Director | 56 | 15.15万美元 | 未持股 | 2023-07-20 |
| Angus C. Russell | 男 | Director | 67 | 14.10万美元 | 未持股 | 2023-07-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary S. Hogge | 男 | Senior Vice President of Clinical & Medical Affairs | 55 | 未披露 | 未持股 | 2023-07-20 |
| Jill A. Howe | 女 | Chief Financial Officer | 47 | 106.04万美元 | 未持股 | 2023-07-20 |
| George A. Samuel III | 男 | General Counsel and Corporate Secretary | 43 | 120.31万美元 | 未持股 | 2023-07-20 |
| Brian M. Culley | 男 | Chief Executive Officer and Director | 52 | 237.25万美元 | 未持股 | 2023-07-20 |
董事简历
中英对照 | 中文 | 英文- Dipti Amin
-
Dipti Amin目前担任赫特福德郡大学的非执行董事，自2018年9月起担任Maaya Associates Ltd.的董事，自2017年8月起担任该职位，并担任白金汉郡NHS Trust的非执行董事，她自2015年6月起担任该职位。Amin博士此前于2017年11月至2020年3月担任Cambridge Innovation Capital的非执行董事。从1995年6月到2016年12月，Amin博士在昆泰跨国公司（Quintiles跨国公司，生物制药开发和商业外包服务的供应商）担任多个高级职位，在药物开发的所有阶段，最近担任高级副总裁兼首席合规官（从2010年4月到2016年12月）。Amin博士在伦敦大学Guys and St.Thomas医院医学院获得医学学位，在皇家全科医师学院获得MRCGP学位，在伦敦皇家内科医师学院药物医学院获得FFPM学位，她的DRCOG形成了皇家妇产科医师学院，她的DGM和DCH来自伦敦皇家内科医师学院，她的DCPSA来自伦敦药剂师学会。
Dipti Amin,currently serves as a non-executive director of the University of Hertfordshire, a position she has held since September 2018. Dr. Amin previously served as a non-executive director of Cambridge Innovation Capital from November 2017 to March 2020, as a director of Maaya Associates Ltd. from August 2017 through the end of 2021, and as a non-executive director of Buckinghamshire NHS Trust, from June 2015 to June 2023. From June 1995 to December 2016, Dr. Amin served at Quintiles Transnational Corporation, a provider of biopharmaceutical development and commercial outsourcing services, in various senior roles within all phases of drug development and most recently as Senior Vice President and Chief Compliance Officer from April 2010 to December 2016. Dr. Amin received her medical degree from Guys and St. Thomas's Hospitals Medical School of the University of London, her MRCGP from the Royal College of General Practitioners, her FFPM from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians London, her DRCOG form the Royal College of Obstetricians and Gynecologists, her DGM and DCH from the Royal College of Physicians, London and her DCPSA from the Society of Apothecaries of London. - Dipti Amin目前担任赫特福德郡大学的非执行董事，自2018年9月起担任Maaya Associates Ltd.的董事，自2017年8月起担任该职位，并担任白金汉郡NHS Trust的非执行董事，她自2015年6月起担任该职位。Amin博士此前于2017年11月至2020年3月担任Cambridge Innovation Capital的非执行董事。从1995年6月到2016年12月，Amin博士在昆泰跨国公司（Quintiles跨国公司，生物制药开发和商业外包服务的供应商）担任多个高级职位，在药物开发的所有阶段，最近担任高级副总裁兼首席合规官（从2010年4月到2016年12月）。Amin博士在伦敦大学Guys and St.Thomas医院医学院获得医学学位，在皇家全科医师学院获得MRCGP学位，在伦敦皇家内科医师学院药物医学院获得FFPM学位，她的DRCOG形成了皇家妇产科医师学院，她的DGM和DCH来自伦敦皇家内科医师学院，她的DCPSA来自伦敦药剂师学会。
- Dipti Amin,currently serves as a non-executive director of the University of Hertfordshire, a position she has held since September 2018. Dr. Amin previously served as a non-executive director of Cambridge Innovation Capital from November 2017 to March 2020, as a director of Maaya Associates Ltd. from August 2017 through the end of 2021, and as a non-executive director of Buckinghamshire NHS Trust, from June 2015 to June 2023. From June 1995 to December 2016, Dr. Amin served at Quintiles Transnational Corporation, a provider of biopharmaceutical development and commercial outsourcing services, in various senior roles within all phases of drug development and most recently as Senior Vice President and Chief Compliance Officer from April 2010 to December 2016. Dr. Amin received her medical degree from Guys and St. Thomas's Hospitals Medical School of the University of London, her MRCGP from the Royal College of General Practitioners, her FFPM from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians London, her DRCOG form the Royal College of Obstetricians and Gynecologists, her DGM and DCH from the Royal College of Physicians, London and her DCPSA from the Society of Apothecaries of London.
- Anula Jayasuriya
-
Anula Jayasuriya是ExxClaim Capital的创始人兼董事总经理，这是一家早期风险基金，专注于促进创新、创业和女性健康投资，她于2013年创立。2006年，她联合创立了Evolvence India Life Science Fund，管理该基金直到2017年7月。从2001年到2002年，Jayasuriya博士是位于帕洛阿尔托的Skyline Ventures的合伙人，此前是位于旧金山的德国/美国风险投资公司TVM的合伙人。她曾担任Genomics Collaborative，Inc.的业务开发副总裁（从1999年到2000年），以及Hoffman-La Roche的全球药物开发副总裁（从1994年到1998年）。Jayasuriya博士以优异成绩获得哈佛大学工商管理硕士学位。剑桥大学药理学博士，哈佛医学院微生物学和分子遗传学硕士，哈佛商学院工商管理硕士。
Anula Jayasuriya,Previously in 2013, Dr. Jayasuriya founded EXXclaim Capital, also focusing on Women's Health. Since May 2021, she has served on the board of directors of Lineage Cell Therapeutics, Inc. (NYSE: LCTX). In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jayasuriya was a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP, Business Development at Genomics Collaborative, Inc., from 1999 to 2000, VP, Global Drug Development at Hoffman-La Roche from 1994 to 1998 and Director, Outcomes Research at Syntex Laboratories. Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School. - Anula Jayasuriya是ExxClaim Capital的创始人兼董事总经理，这是一家早期风险基金，专注于促进创新、创业和女性健康投资，她于2013年创立。2006年，她联合创立了Evolvence India Life Science Fund，管理该基金直到2017年7月。从2001年到2002年，Jayasuriya博士是位于帕洛阿尔托的Skyline Ventures的合伙人，此前是位于旧金山的德国/美国风险投资公司TVM的合伙人。她曾担任Genomics Collaborative，Inc.的业务开发副总裁（从1999年到2000年），以及Hoffman-La Roche的全球药物开发副总裁（从1994年到1998年）。Jayasuriya博士以优异成绩获得哈佛大学工商管理硕士学位。剑桥大学药理学博士，哈佛医学院微生物学和分子遗传学硕士，哈佛商学院工商管理硕士。
- Anula Jayasuriya,Previously in 2013, Dr. Jayasuriya founded EXXclaim Capital, also focusing on Women's Health. Since May 2021, she has served on the board of directors of Lineage Cell Therapeutics, Inc. (NYSE: LCTX). In 2006, she co-founded the Evolvence India Life Science Fund, managing the fund until July of 2017. From 2001 to 2002, Dr. Jayasuriya was a partner with Skyline Ventures in Palo Alto, and prior to that with the German/US venture capital firm TVM, in San Francisco. Her prior positions include VP, Business Development at Genomics Collaborative, Inc., from 1999 to 2000, VP, Global Drug Development at Hoffman-La Roche from 1994 to 1998 and Director, Outcomes Research at Syntex Laboratories. Dr. Jayasuriya received a B.A. from Harvard University summa cum laude, a M. Phil. in pharmacology from the University of Cambridge, an M.D. and Ph.D. (in Microbiology and Molecular Genetics) from Harvard Medical School and an M.B.A. with distinction from Harvard Business School.
- Don M. Bailey
-
Don M. Bailey，他于2006年加入Asterias Biotherapeutics, Inc. 的董事会，担任总裁兼首席执行官。 他于2007年5月被任命为Asterias Biotherapeutics, Inc. 的临时总裁。他在2007年11月被任命为总裁兼首席执行官。他目前是STAAR Surgical Company（采用专有技术的微创眼科产品的开发、制造、销售的领先者）的董事会成员。他曾担任Comarco公司的董事会主席（从1998年到2007年），以及Comarco公司的首席执行官（从1991年到2000年）。他曾担任STAAR公司的董事会主席（从2005年4月到2014年1月）。他持有the Drexel Institute of Technology的机械工程学士学位、南加利福尼亚大学（the University of Southern California）的作业研究硕士学位，以及Pepperdine University的工商管理硕士学位。
Don M. Bailey,previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Bailey served as President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (QCOR), a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, from 2007 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He was also a director of Mallinckrodt plc from August 2014 to March 2016, and during this time he was the Chairman of its portfolio committee. He initially joined the Questcor board of directors in 2006 as an independent director and Chairman of its audit committee. From August 2016 to November 2017, Mr. Bailey served as a director of OncoCyte Corporation (OCX). From June 2015 until its acquisition by Acorda Therapeutics, Inc. (ACOR) in May 2016, Mr. Bailey was also an independent director and chairman of the audit committee of Biotie Therapeutics Corp. (BITI), a clinical-stage pharmaceutical company headquartered in Turku, Finland. Mr. Bailey was an independent director and the non-executive chairman of the board of directors of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from 2005 until 2014. Mr. Bailey served on its audit committee and was chair of its nominating and corporate governance committee. Mr. Bailey was the chairman of the board of directors of Comarco, Inc. (CMRO), a defense services company transformed into a wireless communication products company, from 1998 until 2007, where he served as Chief Executive Officer from 1991 until 2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California and an M.B.A. from Pepperdine University. Mr. Bailey has also served as a board member on several non-profit and academic enterprises. Mr. Bailey is a founding board member of the University of California Irvine's (UCI) Applied Innovation Institute. - Don M. Bailey，他于2006年加入Asterias Biotherapeutics, Inc. 的董事会，担任总裁兼首席执行官。 他于2007年5月被任命为Asterias Biotherapeutics, Inc. 的临时总裁。他在2007年11月被任命为总裁兼首席执行官。他目前是STAAR Surgical Company（采用专有技术的微创眼科产品的开发、制造、销售的领先者）的董事会成员。他曾担任Comarco公司的董事会主席（从1998年到2007年），以及Comarco公司的首席执行官（从1991年到2000年）。他曾担任STAAR公司的董事会主席（从2005年4月到2014年1月）。他持有the Drexel Institute of Technology的机械工程学士学位、南加利福尼亚大学（the University of Southern California）的作业研究硕士学位，以及Pepperdine University的工商管理硕士学位。
- Don M. Bailey,previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Bailey served as President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (QCOR), a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, from 2007 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He was also a director of Mallinckrodt plc from August 2014 to March 2016, and during this time he was the Chairman of its portfolio committee. He initially joined the Questcor board of directors in 2006 as an independent director and Chairman of its audit committee. From August 2016 to November 2017, Mr. Bailey served as a director of OncoCyte Corporation (OCX). From June 2015 until its acquisition by Acorda Therapeutics, Inc. (ACOR) in May 2016, Mr. Bailey was also an independent director and chairman of the audit committee of Biotie Therapeutics Corp. (BITI), a clinical-stage pharmaceutical company headquartered in Turku, Finland. Mr. Bailey was an independent director and the non-executive chairman of the board of directors of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from 2005 until 2014. Mr. Bailey served on its audit committee and was chair of its nominating and corporate governance committee. Mr. Bailey was the chairman of the board of directors of Comarco, Inc. (CMRO), a defense services company transformed into a wireless communication products company, from 1998 until 2007, where he served as Chief Executive Officer from 1991 until 2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California and an M.B.A. from Pepperdine University. Mr. Bailey has also served as a board member on several non-profit and academic enterprises. Mr. Bailey is a founding board member of the University of California Irvine's (UCI) Applied Innovation Institute.
- Neal C. Bradsher
-
Neal C. Bradsher，他是一位注册金融分析师，加入了董事会于2009年7月。自2002年以来他一直是乐活资本公司（一家私人投资公司）的总裁。他持有耶鲁大学的经济学学士学位和是一位注册金融分析师。他亦为QUESTCOR制药公司（一家生物制药公司，侧重于有严重，难以治疗自身免疫性疾病和炎症性疾病的患者的治疗）的董事。
Neal C. Bradsher,has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in many of Lineage's financing transactions. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., currently Lineage Cell Therapeutics, Inc. largest shareholder. - Neal C. Bradsher，他是一位注册金融分析师，加入了董事会于2009年7月。自2002年以来他一直是乐活资本公司（一家私人投资公司）的总裁。他持有耶鲁大学的经济学学士学位和是一位注册金融分析师。他亦为QUESTCOR制药公司（一家生物制药公司，侧重于有严重，难以治疗自身免疫性疾病和炎症性疾病的患者的治疗）的董事。
- Neal C. Bradsher,has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in many of Lineage's financing transactions. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., currently Lineage Cell Therapeutics, Inc. largest shareholder.
- Deborah Andrews
-
Deborah Andrews自2013年9月起任一家上市的生物技术公司BioTime, Inc.的首席会计师，自2014年4月起任董事会和审计委员会成员，该公司专注于再生药物的新兴领域。在这之前，2005年8月至2013年9月Andrews女士曾是STAAR的副总裁兼首席财务官，她从1995年开始就在STAAR工作，2005年4月至2005年8月任STAAR财务总监，2001年至2005年任全球财务总监，1999年至2001年任STAAR Surgical AG Switzerland财务副总裁，1995年至1999年任财务总监助理。1994年至1995年她是电子元件制造商Bourns, Inc.的内部审计员，1991年至1994年是KPMG Peat Marwick的一名审计员。Andrews女士获得了圣贝纳迪诺的California State University的会计学学士学位。
Deborah Andrews,served as Chief Financial Officer of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from September 2017 until June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgical's Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm. Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino. - Deborah Andrews自2013年9月起任一家上市的生物技术公司BioTime, Inc.的首席会计师，自2014年4月起任董事会和审计委员会成员，该公司专注于再生药物的新兴领域。在这之前，2005年8月至2013年9月Andrews女士曾是STAAR的副总裁兼首席财务官，她从1995年开始就在STAAR工作，2005年4月至2005年8月任STAAR财务总监，2001年至2005年任全球财务总监，1999年至2001年任STAAR Surgical AG Switzerland财务副总裁，1995年至1999年任财务总监助理。1994年至1995年她是电子元件制造商Bourns, Inc.的内部审计员，1991年至1994年是KPMG Peat Marwick的一名审计员。Andrews女士获得了圣贝纳迪诺的California State University的会计学学士学位。
- Deborah Andrews,served as Chief Financial Officer of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from September 2017 until June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgical's Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm. Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino.
- Alfred D. Kingsley
-
Alfred D. Kingsley，他加入董事会，成为董事会主席于2009年7月。他是五家公司附属公司的执行董事长。自1993年以来，他一直Greenway Partners有限公司（一家私人投资公司）的普通合伙人，Greenbelt公司（企业咨询公司）的总裁。他担任公司的金融顾问从1998年直到2009年6月30日。他是伊坎公司的高级副总裁超过25年。他是公司附属公司海星生物治疗公司的董事。他持有宾夕法尼亚大学沃顿商学院经济学学士学位，和纽约大学法学院税务法学博士学位和法学硕士学位。
Alfred D. Kingsley,has been Chairman of the Board since July 2009. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt served as Lineage Cell Therapeutics, Inc. financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation (OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer. From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also served as a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York University Law School. - Alfred D. Kingsley，他加入董事会，成为董事会主席于2009年7月。他是五家公司附属公司的执行董事长。自1993年以来，他一直Greenway Partners有限公司（一家私人投资公司）的普通合伙人，Greenbelt公司（企业咨询公司）的总裁。他担任公司的金融顾问从1998年直到2009年6月30日。他是伊坎公司的高级副总裁超过25年。他是公司附属公司海星生物治疗公司的董事。他持有宾夕法尼亚大学沃顿商学院经济学学士学位，和纽约大学法学院税务法学博士学位和法学硕士学位。
- Alfred D. Kingsley,has been Chairman of the Board since July 2009. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt served as Lineage Cell Therapeutics, Inc. financial advisor from 1998 until 2009. Mr. Kingsley also serves as a director of OncoCyte Corporation (OCX), a clinical-stage diagnostics company focused on novel, non-invasive blood-based tests for the early detection of cancer. From January 2017 to October 2018, Mr. Kingsley served as Executive Chairman of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Kingsley also served as a director of Asterias Biotherapeutics, Inc. (AST) from 2012 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a B.S. degree in economics from the Wharton School of the University of Pennsylvania and a J.D. degree and LLM in taxation from New York University Law School.
- Brian M. Culley
-
Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University. - Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
- Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.
- Michael H. Mulroy
-
Michael H. Mulroy，自2017年6月起担任Asterias Biotherapeutics, Inc.（AST）的首席执行官和董事会成员，直至Lineage Cell Therapeutics，Inc.于2019年3月收购Asterias。2020年4月，Mulroy先生兼职加入Magtrol Inc.，这是一家领先的电机测试设备和迟滞制动器和离合器制造商，他还担任该公司的董事会成员。在加入Asterias之前，Mulroy先生曾担任CamberView Partners，LLC（现为PJT Partners Inc.的一部分）的高级顾问，CamberView Partners，LLC在投资者参与和复杂的公司治理问题方面为公司提供协助。在2014年出售之前，Mulroy先生曾担任Questcor Pharmaceuticals, Inc.（QCOR）的执行副总裁、战略事务和总法律顾问兼公司秘书。Mulroy先生于2011年加入Questcor，担任首席财务官、总法律顾问和公司秘书。2017年1月至2019年7月，Mulroy先生担任AgeX Terapeutics，Inc.（AGE）的董事会成员，AgeX Therapeutics，Inc.是一家生物技术公司，专注于针对人类衰老的新型疗法的开发和商业化。Mulroy先生获得了加州大学洛杉矶分校的法学博士学位和芝加哥大学的经济学学士学位。
Michael H. Mulroy,served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. (AST) from June 2017 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. In April 2020, Mr. Mulroy joined Magtrol Inc., a leading manufacturer of motor test equipment and hysteresis brakes and clutches, on a part-time basis, where he also serves on its board of directors. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor Pharmaceuticals, Inc. (QCOR). Mr. Mulroy joined Questcor in 2011 as Chief Financial Officer, General Counsel and Corporate Secretary. From January 2017 to July 2019, Mr. Mulroy served as a member of the board of directors of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago. - Michael H. Mulroy，自2017年6月起担任Asterias Biotherapeutics, Inc.（AST）的首席执行官和董事会成员，直至Lineage Cell Therapeutics，Inc.于2019年3月收购Asterias。2020年4月，Mulroy先生兼职加入Magtrol Inc.，这是一家领先的电机测试设备和迟滞制动器和离合器制造商，他还担任该公司的董事会成员。在加入Asterias之前，Mulroy先生曾担任CamberView Partners，LLC（现为PJT Partners Inc.的一部分）的高级顾问，CamberView Partners，LLC在投资者参与和复杂的公司治理问题方面为公司提供协助。在2014年出售之前，Mulroy先生曾担任Questcor Pharmaceuticals, Inc.（QCOR）的执行副总裁、战略事务和总法律顾问兼公司秘书。Mulroy先生于2011年加入Questcor，担任首席财务官、总法律顾问和公司秘书。2017年1月至2019年7月，Mulroy先生担任AgeX Terapeutics，Inc.（AGE）的董事会成员，AgeX Therapeutics，Inc.是一家生物技术公司，专注于针对人类衰老的新型疗法的开发和商业化。Mulroy先生获得了加州大学洛杉矶分校的法学博士学位和芝加哥大学的经济学学士学位。
- Michael H. Mulroy,served as the Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc. (AST) from June 2017 until Lineage Cell Therapeutics, Inc. acquisition of Asterias in March 2019. In April 2020, Mr. Mulroy joined Magtrol Inc., a leading manufacturer of motor test equipment and hysteresis brakes and clutches, on a part-time basis, where he also serves on its board of directors. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC (now part of PJT Partners Inc.), which assists companies in connection with investor engagement and complex corporate governance issues. Prior to its sale in 2014, Mr. Mulroy served as Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor Pharmaceuticals, Inc. (QCOR). Mr. Mulroy joined Questcor in 2011 as Chief Financial Officer, General Counsel and Corporate Secretary. From January 2017 to July 2019, Mr. Mulroy served as a member of the board of directors of AgeX Therapeutics, Inc. (AGE), a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. degree in economics from the University of Chicago.
- Angus C. Russell
-
Angus C. Russell自2011年10月起担任董事会成员。2008年6月至2013年4月其退休，他担任生物制药公司Shire plc（“Shire”）的首席执行官，并且曾是其董事会1999年至2013年的成员。1999年12月至2008年6月他担任Shire的首席财务官。他是一位City of London Investment Trust plc的前非执行董事。他是一名特许会计师以及Association of Corporate Treasurers的一位会员。
Angus C. Russell,served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN). Mr. Russell also serves as Chairman of the Board of Directors of Revance Therapeutics, Inc. (RVNC). Mr. Russell previously served as a director of Shire plc, Questcor Pharmaceuticals, Inc. (QCOR) until it was acquired by Mallinckrodt plc (MNK) in 2014, InterMune, Inc. (ITMN) prior to its acquisition by Roche Holdings, Inc. (RHHBY) in 2014, Mallinckrodt plc (MNK) until June of 2022 and Therapeutics MD, Inc. (TXMD) until December 2022. Mr. Russell holds an honorary Doctor of Business Administration from Coventry University; U.K. - Angus C. Russell自2011年10月起担任董事会成员。2008年6月至2013年4月其退休，他担任生物制药公司Shire plc（“Shire”）的首席执行官，并且曾是其董事会1999年至2013年的成员。1999年12月至2008年6月他担任Shire的首席财务官。他是一位City of London Investment Trust plc的前非执行董事。他是一名特许会计师以及Association of Corporate Treasurers的一位会员。
- Angus C. Russell,served as the Chief Executive Officer of Shire plc (SHPG), a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca for 19 years, most recently as Vice President of Corporate Finance at AstraZeneca plc (AZN). Mr. Russell also serves as Chairman of the Board of Directors of Revance Therapeutics, Inc. (RVNC). Mr. Russell previously served as a director of Shire plc, Questcor Pharmaceuticals, Inc. (QCOR) until it was acquired by Mallinckrodt plc (MNK) in 2014, InterMune, Inc. (ITMN) prior to its acquisition by Roche Holdings, Inc. (RHHBY) in 2014, Mallinckrodt plc (MNK) until June of 2022 and Therapeutics MD, Inc. (TXMD) until December 2022. Mr. Russell holds an honorary Doctor of Business Administration from Coventry University; U.K.
高管简历
中英对照 | 中文 | 英文- Gary S. Hogge
Gary S.霍格于2018年2月加入EAGE，担任临床和医疗事务高级副总裁。Hogge博士拥有20年的经验，在广泛的治疗领域开发和支持多个产品的商业化。Hogge博士在临床开发和医疗事务的多个治疗领域担任着各种职责递增的角色。此前，霍格博士是QuestcorPharmaceuticals，Inc.医疗事务Vice President。在此之前，QCOR在Elan Pharmaceuticals的临床开发和医疗事务中担任多个领导职务，包括在Crohn&8217；s病和多发性硬化症的Tysabri&174；（Natalizumab）的全球临床开发中的各种职责，以及建立和领导医疗事务职能。他曾担任Tysabri公司的批准和上市后的医疗董事。在取得这些成就之前，他曾在Maxim Pharmaceuticals的Ceplene®；（盐酸组胺）和辉瑞公司的免疫学研究与开发小组从事临床开发工作。Hogge博士在科罗拉多州立大学（Colorado State University）获得B.S.学位和D.V.M.，在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得M.S.和博士学位，是澳大利亚布里斯班昆士兰医学研究所（QIMR）的客座科学家。
Gary S. Hogge,joined Lineage as Senior Vice President of Clinical and Medical Affairs in February 2018. Dr. Hogge has more than 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at Questcor Pharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri (natalizumab) in Crohn's disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his B.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia.- Gary S.霍格于2018年2月加入EAGE，担任临床和医疗事务高级副总裁。Hogge博士拥有20年的经验，在广泛的治疗领域开发和支持多个产品的商业化。Hogge博士在临床开发和医疗事务的多个治疗领域担任着各种职责递增的角色。此前，霍格博士是QuestcorPharmaceuticals，Inc.医疗事务Vice President。在此之前，QCOR在Elan Pharmaceuticals的临床开发和医疗事务中担任多个领导职务，包括在Crohn&8217；s病和多发性硬化症的Tysabri&174；（Natalizumab）的全球临床开发中的各种职责，以及建立和领导医疗事务职能。他曾担任Tysabri公司的批准和上市后的医疗董事。在取得这些成就之前，他曾在Maxim Pharmaceuticals的Ceplene®；（盐酸组胺）和辉瑞公司的免疫学研究与开发小组从事临床开发工作。Hogge博士在科罗拉多州立大学（Colorado State University）获得B.S.学位和D.V.M.，在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得M.S.和博士学位，是澳大利亚布里斯班昆士兰医学研究所（QIMR）的客座科学家。
- Gary S. Hogge,joined Lineage as Senior Vice President of Clinical and Medical Affairs in February 2018. Dr. Hogge has more than 20 years of experience developing and supporting the commercialization of a number of products over a broad range of therapeutic areas. Dr. Hogge has held a variety of roles of increasing responsibility across multiple therapeutic areas in both clinical development and medical affairs. Previously Dr. Hogge was the Vice President of Medical Affairs at Questcor Pharmaceuticals, Inc. (QCOR) and before that held multiple leadership roles in both clinical development and medical affairs at Elan Pharmaceuticals including various responsibilities in the global clinical development of Tysabri (natalizumab) in Crohn's disease and multiple sclerosis, and for building and leading the medical affairs function. He served as medical director following the approval and launch of Tysabri. Prior to those accomplishments, he worked in clinical development for Ceplene (histamine dihydrochloride) at Maxim Pharmaceuticals and in the immunology research and development group at Pfizer. Dr. Hogge obtained his B.S. degree and D.V.M. from Colorado State University, his M.S. and Ph.D. from the University of Wisconsin-Madison and was a visiting scientist at the Queensland Institute of Medical Research (QIMR) in Brisbane, Australia.
- Jill A. Howe
Jill A. Howe，于2022年11月14日加入Lineage，担任首席财务官。在加入Lineage之前，豪女士最近担任生物技术公司DTx Pharma，Inc.的首席财务官，她从2021年6月至2022年7月担任该职位。在加入DTx Pharma之前，从2018年1月至2021年6月，豪女士担任Gossamer Bio, Inc.（纳斯达克：GOSS）的财务副总裁兼财务主管，这是一家处于临床阶段的生物制药公司。在加入Gossamer Bio之前，她于2016年3月至2017年12月担任生物制药公司Amplyx Pharmaceuticals，Inc.的财务总监兼财务总监。她曾在生物技术公司Receptos, Inc.和专业制药公司Somaxon制药担任财务总监和财务总监。自2021年11月起，豪女士担任Biora Therapeutics, Inc.（纳斯达克：BIOR）董事会成员、审计委员会主席和提名委员会成员，并自2021年10月起担任Codagenix公司董事会成员。豪女士在圣迭戈州立大学获得会计学学士学位。
Jill A. Howe,joined Lineage as Chief Financial Officer on November 14, 2022. Before joining Lineage, Ms. Howe most recently served as the Chief Financial Officer of DTx Pharma, Inc., a biotechnology company, a position she held from June 2021 through July 2022. Prior to joining DTx Pharma, from January 2018 to June 2021, Ms. Howe served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company. Prior to Gossamer Bio, she served as Controller & Director of Finance of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company, from March 2016 to December 2017. She previously held positions, including as Controller and Director of Finance, at Receptos, Inc., a biotechnology company, and at Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. Since November 2021, Ms. Howe has served on the board of directors of, and as the chair of the audit committee and as a member of the nominating committee of, Biora Therapeutics, Inc. (Nasdaq: BIOR), and since October 2021, has served on the board of directors of Codagenix Inc. Ms. Howe earned a B.S. in Accountancy from San Diego State University.- Jill A. Howe，于2022年11月14日加入Lineage，担任首席财务官。在加入Lineage之前，豪女士最近担任生物技术公司DTx Pharma，Inc.的首席财务官，她从2021年6月至2022年7月担任该职位。在加入DTx Pharma之前，从2018年1月至2021年6月，豪女士担任Gossamer Bio, Inc.（纳斯达克：GOSS）的财务副总裁兼财务主管，这是一家处于临床阶段的生物制药公司。在加入Gossamer Bio之前，她于2016年3月至2017年12月担任生物制药公司Amplyx Pharmaceuticals，Inc.的财务总监兼财务总监。她曾在生物技术公司Receptos, Inc.和专业制药公司Somaxon制药担任财务总监和财务总监。自2021年11月起，豪女士担任Biora Therapeutics, Inc.（纳斯达克：BIOR）董事会成员、审计委员会主席和提名委员会成员，并自2021年10月起担任Codagenix公司董事会成员。豪女士在圣迭戈州立大学获得会计学学士学位。
- Jill A. Howe,joined Lineage as Chief Financial Officer on November 14, 2022. Before joining Lineage, Ms. Howe most recently served as the Chief Financial Officer of DTx Pharma, Inc., a biotechnology company, a position she held from June 2021 through July 2022. Prior to joining DTx Pharma, from January 2018 to June 2021, Ms. Howe served as Vice President of Finance and Treasurer for Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company. Prior to Gossamer Bio, she served as Controller & Director of Finance of Amplyx Pharmaceuticals, Inc., a biopharmaceutical company, from March 2016 to December 2017. She previously held positions, including as Controller and Director of Finance, at Receptos, Inc., a biotechnology company, and at Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company. Since November 2021, Ms. Howe has served on the board of directors of, and as the chair of the audit committee and as a member of the nominating committee of, Biora Therapeutics, Inc. (Nasdaq: BIOR), and since October 2021, has served on the board of directors of Codagenix Inc. Ms. Howe earned a B.S. in Accountancy from San Diego State University.
- George A. Samuel III
乔治·A·塞缪尔三世于2021年9月1日加入Lineage，担任总法律顾问和公司秘书。在加入Lineage之前，Samuel先生最近担任Lytx，Inc.董事兼高级法律顾问，负责管理一家国际视频远程信息处理SaaS公司的商业法律业务，他于2020年1月至2021年8月担任该职位。从2019年2月到2019年12月，Samuel先生在VLP Law Group LLC从事公司法工作。从2016年8月至2019年2月，Samuel先生担任Cardiff Oncology, Inc.（前称Trovagene，Inc.）的副总裁、总法律顾问和公司秘书，这是一家临床阶段的生物技术公司，专注于开发肿瘤治疗。在Cardiff Oncology工作期间，他为战略、业务发展和运营决策提供咨询；监督筹资工作、监管合规以及SEC报告；管理知识产权，包括技术转让和许可。Samuel先生还在Cooley LLP、DLA Piper LLP和Winston & Strawn LLP从事公司法工作，在各种商业交易中担任上市公司和私营公司的外部法律顾问。塞缪尔先生在哥伦比亚大学法学院获得法学博士学位，在塔夫茨大学获得哲学学士学位，并且是加利福尼亚州和纽约州律师协会的成员。
George A. Samuel III,joined Lineage as General Counsel and Corporate Secretary on September 1, 2021. Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company, a position he held from January 2020 to August 2021. From February 2019 to December 2019, Mr. Samuel practiced corporate law at VLP Law Group LLC. From August 2016 to February 2019, Mr. Samuel served as VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc. (formerly known as Trovagene, Inc.), a clinical-stage biotechnology company focused on developing treatments in oncology. While at Cardiff Oncology, he advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance as well as SEC reporting; and managed intellectual property, including technology transfer and licensing. Mr. Samuel has also practiced corporate law at Cooley LLP, DLA Piper LLP, and Winston & Strawn LLP, where he served as outside counsel to public and private companies in a variety of commercial transactions. Mr. Samuel received a J.D. from Columbia University School of Law, and a B.A. in Philosophy from Tufts University and is a member of the State Bar of California and New York.- 乔治·A·塞缪尔三世于2021年9月1日加入Lineage，担任总法律顾问和公司秘书。在加入Lineage之前，Samuel先生最近担任Lytx，Inc.董事兼高级法律顾问，负责管理一家国际视频远程信息处理SaaS公司的商业法律业务，他于2020年1月至2021年8月担任该职位。从2019年2月到2019年12月，Samuel先生在VLP Law Group LLC从事公司法工作。从2016年8月至2019年2月，Samuel先生担任Cardiff Oncology, Inc.（前称Trovagene，Inc.）的副总裁、总法律顾问和公司秘书，这是一家临床阶段的生物技术公司，专注于开发肿瘤治疗。在Cardiff Oncology工作期间，他为战略、业务发展和运营决策提供咨询；监督筹资工作、监管合规以及SEC报告；管理知识产权，包括技术转让和许可。Samuel先生还在Cooley LLP、DLA Piper LLP和Winston & Strawn LLP从事公司法工作，在各种商业交易中担任上市公司和私营公司的外部法律顾问。塞缪尔先生在哥伦比亚大学法学院获得法学博士学位，在塔夫茨大学获得哲学学士学位，并且是加利福尼亚州和纽约州律师协会的成员。
- George A. Samuel III,joined Lineage as General Counsel and Corporate Secretary on September 1, 2021. Prior to joining Lineage, Mr. Samuel most recently served as Director, Senior Counsel for Lytx, Inc., where he managed the commercial legal operations for an international video telematics SaaS company, a position he held from January 2020 to August 2021. From February 2019 to December 2019, Mr. Samuel practiced corporate law at VLP Law Group LLC. From August 2016 to February 2019, Mr. Samuel served as VP, General Counsel and Corporate Secretary for Cardiff Oncology, Inc. (formerly known as Trovagene, Inc.), a clinical-stage biotechnology company focused on developing treatments in oncology. While at Cardiff Oncology, he advised on strategic, business development and operational decisions; oversaw capital raising efforts, regulatory compliance as well as SEC reporting; and managed intellectual property, including technology transfer and licensing. Mr. Samuel has also practiced corporate law at Cooley LLP, DLA Piper LLP, and Winston & Strawn LLP, where he served as outside counsel to public and private companies in a variety of commercial transactions. Mr. Samuel received a J.D. from Columbia University School of Law, and a B.A. in Philosophy from Tufts University and is a member of the State Bar of California and New York.
- Brian M. Culley
Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.- Brian M. Culley， 自2010年2月以来，担任本公司的首席执行官。自2011年12月以来，是本公司董事会的成员。自2009年2月以来，是本公司的行政主管。此前，他曾于2007年1月-2010年2月期间，担任本公司的商务总监和高级副总裁；2006年2月-2007年1月期间，曾担任本公司的商业开发高级副总裁；以及2004年12月-2006年2月期间，曾担任本公司的商业开发副总裁。2002-2004年期间，曾在San Diego市的iTherx股份有限公司（原为Immusol股份有限公司）管理所有的战略合作和许可协议，最近的职位是商业开发和营销总监。1999-2000年期间，曾是San Diego市加州大学（University of California）技术转让&和知识产权服务系的许可和营销准学士；1996-1999年期间，曾是Neurocrine Biosciences股份有限公司的一位研究助理。他拥有着超过20年的生命科学行业经验。他是在Boston大学获得生物学学士学位、在Santa Barbara市加州大学（University of California）获得生物化学硕士学位，以及在Cornell大学Johnson商学院获得工商管理学硕士学位的。
- Brian M. Culley,joined Lineage as Chief Executive Officer in September 2018 and served as Interim Chief Financial Officer from January 20, 2021 to June 21, 2021 and from July 8, 2022 to November 14, 2022. Prior to joining Lineage, Mr. Culley served from August 2017 to September 2018 as interim Chief Executive Officer at Artemis Therapeutics, Inc. (ATMS). Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast's merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from 2007 to 2010 as Mast's Chief Business Officer and Senior Vice President, from 2006 to 2007 as Mast's Senior Vice President, Business Development, and from 2004 to 2006 as Mast's Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. (NBIX). Mr. Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022. Mr. Culley has more than 30 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.